Acorda Therapeutics
ACORNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for ACOR. That does not mean none is planned.
Get an email about ACOR's next catalysts
Track Acorda Therapeutics (ACOR) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
Market Overview
Stock performance and key metrics
CVT-301
Idiopathic Parkinson's Disease
dalfampridine-ER
Post-Ischemic Stroke
Fampridine-SR
Multiple Sclerosis
CVT-301 Low Dose
Idiopathic Parkinson's Disease
Fampridine-SR b.i.d. (Twice Daily)
Multiple Sclerosis
Dalfampridine Pill
Multiple Sclerosis
CVT-301 High Dose
Idiopathic Parkinson's Disease
Sinemet (carbidopa/levodopa)
Idiopathic Parkinson's Disease
Dalfampridine
Spinal Cord Injury
Nepicastat
Posttraumatic Stress Disorder
10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP)
Multiple Sclerosis
Tizanidine
Spasticity
Diazepam
Epilepsy
fampridine-SR (4-aminopyridine, 4-AP)
Multiple Sclerosis
SYN120
Parkinson's Disease Dementia (PDD)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CVT-301 | Phase 3 | Idiopathic Parkinson's Disease | - | - |
dalfampridine-ER | Phase 3 | Post-Ischemic Stroke | - | - |
Fampridine-SR | Phase 3 | Multiple Sclerosis | - | - |
CVT-301 Low Dose | Phase 3 | Idiopathic Parkinson's Disease | - | - |
Fampridine-SR b.i.d. (Twice Daily) | Phase 3 | Multiple Sclerosis | - | - |
Dalfampridine Pill | Phase 3 | Multiple Sclerosis | - | - |
CVT-301 High Dose | Phase 3 | Idiopathic Parkinson's Disease | - | - |
Sinemet (carbidopa/levodopa) | Phase 2 | Idiopathic Parkinson's Disease | - | - |
Dalfampridine | Phase 2 | Spinal Cord Injury | - | - |
Nepicastat | Phase 2 | Posttraumatic Stress Disorder | - | - |
10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP) | Phase 2 | Multiple Sclerosis | - | - |
Tizanidine | Phase 2 | Spasticity | - | - |
Diazepam | Phase 2 | Epilepsy | - | - |
fampridine-SR (4-aminopyridine, 4-AP) | Phase 2 | Multiple Sclerosis | - | - |
SYN120 | Phase 2 | Parkinson's Disease Dementia (PDD) | - | - |
Frequently asked questions
What is in Acorda Therapeutics's drug pipeline?β
CatalystAlert tracks 15 drug candidates in Acorda Therapeutics's (ACOR) pipeline across Phase 3, Phase 2. Its lead program is CVT-301 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Acorda Therapeutics's next FDA catalyst?β
CatalystAlert tracks every upcoming catalyst for Acorda Therapeutics (ACOR) β PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β each confidence-rated as confirmed, estimated or AI-detected.
How do I track ACOR biotech catalysts?β
Add ACOR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Acorda Therapeutics's live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
